For Patients & Caregivers

Dosing Calculator

Calculate HEMLIBRA loading and maintenance doses

Use this calculator as a guide to help determine your patient’s weight-based dose of HEMLIBRA. The calculator provides recommendations for vial combinations, calculated to achieve the required dose with either the minimum amount of wasted drug product or the minimum number of injections. Then, you can print the results once you’re finished.

For patients starting HEMLIBRA, they should receive a loading dose of 3 mg/kg once weekly for the first 4 weeks.1

At Week 5, your patient starts on 1 of the chosen maintenance dosing options: every week, every 2 weeks, or every 4 weeks.1

See HEMLIBRA dosing options.

Weights will be calculated up to one decimal point.

Weight unit

Thank you

Your request has been submitted.
Least Injections
Least Wastage
Print

Least Injections

Loading Dose
(Weeks 1-4)

The information provided is not a substitute for clinical judgment. By using this resource, you agree to the following: This Dosing Calculator is being provided “AS IS” and is intended for use only by qualified healthcare providers. Confirm all calculations before use. Genentech makes no claims as to the accuracy of the information contained herein. Neither Genentech nor any other party involved in preparation or publication of this site shall be liable to you or others for any decisions made or actions taken by you or others in reliance of this information.

Suggested dosage and vial combinations provided by the calculator are based on the nearest whole 1 kg in weight. Weights ending in decimals 0.0 to 0.4 have been rounded down to the nearest whole number and weights ending in decimals 0.5 to 0.9 have been rounded up to the nearest whole number. Weights entered in lbs will be converted to the nearest whole kg.

Calculated dosage volume may vary depending on the choice of vial combination and volume drawn from each vial.

Do not combine HEMLIBRA vials of different concentrations in a single injection. The 12 mg/0.4 mL and 30 mg/mL vials are 30 mg/mL in concentration, and the 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/mL, and 300 mg/2 mL vials are 150 mg/mL in concentration.1,33

Administer doses of HEMLIBRA up to 1 mL with a 1-mL syringe. Administer doses of HEMLIBRA greater than 1 mL and up to 2 mL with a 2-mL or 3-mL syringe.1

Discard any unused solution in the vial after each use.1

This tool has been programmed to calculate suggested dosages and display suggested vial combinations for weights between 2.5-150 kg. This tool cannot be used to calculate the dosage and display suggested vial combinations for weights that fall outside of this range. There is no weight restriction or weight limitation for the use of HEMLIBRA in the treatment of patients with hemophilia A. There may be additional dosing options for the patient. The information provided is not a substitution for clinical judgment.

Print

Least Injections

Maintenance Dose Options
(Weeks 5+)
Print

Least Wastage

Loading Dose
(Weeks 1-4)
Print

Least Wastage

Maintenance Dose Options
(Weeks 5+)

Watch a step-by-step injection demonstration video for your patients

Go Now

Get Financial Support

HEMLIBRA offers several forms of assistance that may be suitable for you.

Explore the Resources

Half-Life & Pharmacokinetics

Learn more about the unique and extended half-life of HEMLIBRA.

See the Data
NEXT: Supplies & Storage

Indication & Important Safety Information

Indication
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.

Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur. 

Warnings and Precautions
Thrombotic Microangiopathy (TMA) and Thromboembolism Associated With HEMLIBRA and aPCC
In clinical trials, TMA was reported in 0.8% of patients (3/391) and thrombotic events were reported in 0.5% of patients (2/391). In patients who received at least one dose of aPCC, TMA was reported in 8.1% of patients (3/37) and thrombotic events were reported in 5.4% of patients (2/37). Patients with TMA presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13.

Consider the benefits and risks if aPCC must be used in a patient receiving HEMLIBRA prophylaxis. Due to the long half-life of HEMLIBRA, the potential for an interaction with aPCC may persist for up to 6 months after the last dose. Monitor for the development of TMA and/or thromboembolism when administering aPCC. Immediately discontinue aPCC and interrupt HEMLIBRA prophylaxis if clinical symptoms, imaging, or laboratory findings consistent with TMA and/or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of TMA and/or thrombotic events on a case-by-case basis.

Immunogenicity
Treatment with HEMLIBRA may induce anti-drug antibodies. Anti-emicizumab-kxwh antibodies were reported in 5.1% of patients (34/668) treated with HEMLIBRA in clinical trials. Most patients with anti-emicizumab-kxwh antibodies did not experience a change in HEMLIBRA plasma concentrations or an increase in bleeding events; however, in uncommon cases (incidence <1%), the presence of neutralizing antibodies with decreasing plasma concentration may be associated with loss of efficacy.

Monitor for clinical signs of loss of efficacy (eg, increase in breakthrough bleeding events) and if observed, promptly assess the etiology and consider a change in treatment if neutralizing anti-emicizumab-kxwh antibodies are suspected.

Laboratory Coagulation Test Interference
HEMLIBRA affects intrinsic pathway clotting-based laboratory tests, including activated clotting time (ACT); activated partial thromboplastin time (aPTT); and all assays based on aPTT, such as one-stage, factor VIII (FVIII) activity. Therefore, intrinsic pathway clotting-based coagulation laboratory test results in patients who have been treated with HEMLIBRA prophylaxis should not be used to monitor HEMLIBRA activity, determine dosing for factor replacement or anti-coagulation, or measure FVIII inhibitor titers.

Results affected by HEMLIBRA: aPTT; Bethesda assays (clotting-based) for FVIII inhibitor titers; one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); ACT.

Results unaffected by HEMLIBRA: Bethesda assays (bovine chromogenic) for FVIII inhibitor titers; thrombin time (TT); one-stage, prothrombin time (PT)-based single-factor assays; chromogenic-based single-factor assays other than FVIII (see Drug Interactions for FVIII chromogenic activity assay considerations); immuno-based assays (ie, ELISA, turbidimetric methods); genetic tests of coagulation factors (eg, Factor V Leiden, Prothrombin 20210).

Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.

Adverse Reactions
Characterization of aPCC Treatment in Pooled Clinical Trials
There were 130 instances of aPCC treatment in 37 patients, of which 13 instances (10%) consisted of on average a cumulative amount of >100 U/kg/24 hours of aPCC for 24 hours or more; 2 of the 13 were associated with thrombotic events and 3 of the 13 were associated with TMA. No TMA or thrombotic events were associated with the remaining instances of aPCC treatment.

Injection Site Reactions
In total, 85 patients (22%) reported injection site reactions (ISRs). All ISRs observed in HEMLIBRA clinical trials were reported as mild to moderate intensity and 93% resolved without treatment. The commonly reported ISR symptoms were injection site erythema (11%), injection site pruritus (4%), and injection site pain (4%).

Other Less Common (<1%) Reactions
Rhabdomyolysis was reported in 2 adult patients with asymptomatic elevations in serum creatine kinase without associated renal or musculoskeletal symptoms. In both instances, the event occurred following an increase in physical activity.

Drug Interactions
Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC.

Pregnancy, Lactation, Females and Males of Reproductive Potential
Women of childbearing potential should use contraception while receiving HEMLIBRA. It is not known whether HEMLIBRA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HEMLIBRA should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for HEMLIBRA and any potential adverse effects on the breastfed child from HEMLIBRA or from the underlying maternal condition.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.

    • HEMLIBRA package insert. South San Francisco, CA: Genentech, Inc.; 2025.

      HEMLIBRA package insert. South San Francisco, CA: Genentech, Inc.; 2025.

    • FDA Approves Genentech’s HEMLIBRA (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors. Genentech Press Release. South San Francisco, CA: Genentech; October 4, 2018.

      FDA Approves Genentech’s HEMLIBRA (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors. Genentech Press Release. South San Francisco, CA: Genentech; October 4, 2018.

    • Data on File. Genentech, Inc.

      Data on File. Genentech, Inc.

    • Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127​​-2138. doi:10.1182/blood.2019001869

      Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127​​-2138. doi:10.1182/blood.2019001869

    • Young G, Sidonio R, Oldenburg J, et al. Efficacy/safety in children on 2/4-weekly emicizumab prophylaxis: 52-week outcomes in HAVEN 2. Presented at the American Society of Pediatric Hematology/Oncology (ASPHO) Conference; May 4​-7, 2022; Pittsburgh, Pennsylvania.

      Young G, Sidonio R, Oldenburg J, et al. Efficacy/safety in children on 2/4-weekly emicizumab prophylaxis: 52-week outcomes in HAVEN 2. Presented at the American Society of Pediatric Hematology/Oncology (ASPHO) Conference; May 4​-7, 2022; Pittsburgh, Pennsylvania.

    • Shima M, Nagao A, Taki M, et al. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: a phase 1/2 study in patients with severe haemophilia A. Haemophilia. 2021;27(1):81​-89. doi:10.1111/hae.14205

      Shima M, Nagao A, Taki M, et al. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: a phase 1/2 study in patients with severe haemophilia A. Haemophilia. 2021;27(1):81​-89. doi:10.1111/hae.14205

    • Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25(6):979​-987. doi:10.1111/hae.13848

      Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25(6):979​-987. doi:10.1111/hae.13848

    • Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023;10(3):e168-e177. doi:10.1016/S2352-3026(22)00377-5

      Négrier C, Mahlangu J, Lehle M, et al. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023;10(3):e168-e177. doi:10.1016/S2352-3026(22)00377-5

    • Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143(14):1355-1364. doi:10.1182/blood.2023021832

      Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024;143(14):1355-1364. doi:10.1182/blood.2023021832

    • Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost. 2022;6(8):e12837. doi:10.1002/rth2.12837

      Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: a phase 3b, multicenter, single-arm study (STASEY). Res Pract Thromb Haemost. 2022;6(8):e12837. doi:10.1002/rth2.12837

    • Efficacy, safety, and pharmacokinetic study of prophylactic emicizumab versus no prophylaxis in hemophilia A participants (HAVEN 5). Clinicaltrials.gov identifier: NCT03315455. Updated September 25, 2024. Accessed July 7, 2026. https://clinicaltrials.gov/ct2/show/NCT03315455.

      Efficacy, safety, and pharmacokinetic study of prophylactic emicizumab versus no prophylaxis in hemophilia A participants (HAVEN 5). Clinicaltrials.gov identifier: NCT03315455. Updated September 25, 2024. Accessed July 7, 2026. https://clinicaltrials.gov/ct2/show/NCT03315455.

    • Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017:117(7):1348​-1357. doi:10.1160/TH17-01-0030

      Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017:117(7):1348​-1357. doi:10.1160/TH17-01-0030

    • Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Supplement. Blood. 2021;137(16):2231​​-2242. doi:10.1182/blood.2020009217

      Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Supplement. Blood. 2021;137(16):2231​​-2242. doi:10.1182/blood.2020009217

    • Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231​​-2242. doi:10.1182/blood.2020009217

      Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137(16):2231​​-2242. doi:10.1182/blood.2020009217

    • National Bleeding Disorders Foundation. MASAC Document 268: Recommendation on the use and management of emicizumab-kxwh (HEMLIBRA) for hemophilia A with and without inhibitors. April 27, 2022; New York, NY.

      National Bleeding Disorders Foundation. MASAC Document 268: Recommendation on the use and management of emicizumab-kxwh (HEMLIBRA) for hemophilia A with and without inhibitors. April 27, 2022; New York, NY.

    • McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631-636. doi:10.1111/hae.14005

      McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631-636. doi:10.1111/hae.14005

    • Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood. 2022;6(24):6140-6150. doi:10.1182/bloodadvances.2022007458

      Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood. 2022;6(24):6140-6150. doi:10.1182/bloodadvances.2022007458

    • Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818. doi:10.1056/NEJMoa1703068

      Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818. doi:10.1056/NEJMoa1703068

    • Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. Supplement. N Engl J Med. 2017;377(9):809-818. doi:10.1056/NEJMoa1703068

      Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. Supplement. N Engl J Med. 2017;377(9):809-818. doi:10.1056/NEJMoa1703068

    • Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2020;26(1):41-46. doi:10.1111/hae.13877

      Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2020;26(1):41-46. doi:10.1111/hae.13877

    • Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia. 2021;27(6):e698-e703. doi:10.1111/hae.14432

      Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia. 2021;27(6):e698-e703. doi:10.1111/hae.14432

    • Schmitt C, Emrich T, Chebon S, et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 2021;27(6):984-992. doi:10.1111/hae.14398

      Schmitt C, Emrich T, Chebon S, et al. Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 2021;27(6):984-992. doi:10.1111/hae.14398

    • Mahlangu J, Jiménez-Yuste V, Ventriglia G, et al. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Res Pract Thromb Haemost. 2024;8(2):102364. doi:10.1016/j.rpth.2024.102364

      Mahlangu J, Jiménez-Yuste V, Ventriglia G, et al. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Res Pract Thromb Haemost. 2024;8(2):102364. doi:10.1016/j.rpth.2024.102364

    • Di Minno A, Spadarella G, Nardone A, et al. Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient’s joint status. Blood Rev. 2019;33:106-116. doi:10.1016/j.blre.2018.08.003

      Di Minno A, Spadarella G, Nardone A, et al. Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient’s joint status. Blood Rev. 2019;33:106-116. doi:10.1016/j.blre.2018.08.003

    • Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia. 2016;22(4):499-506. doi:10.1111/hae.12904

      Schrijvers LH, Schuurmans MJ, Fischer K. Promoting self-management and adherence during prophylaxis: evidence-based recommendations for haemophilia professionals. Haemophilia. 2016;22(4):499-506. doi:10.1111/hae.12904

    • Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. doi:10.1056/NEJMoa067659

      Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544. doi:10.1056/NEJMoa067659

    • National Bleeding Disorders Foundation. MASAC Document 267: MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. April 27, 2022; New York, NY.

      National Bleeding Disorders Foundation. MASAC Document 267: MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors. April 27, 2022; New York, NY.

    • Pipe S, Collins P, Dhalluin C, et al. Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study. Slide deck presented at: 65th ASH Annual Meeting; December 9-12, 2023; San Diego, California.

      Pipe S, Collins P, Dhalluin C, et al. Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study. Slide deck presented at: 65th ASH Annual Meeting; December 9-12, 2023; San Diego, California.

    • Ljung R, de Kovel M, van den Berg HM on behalf of the PedNet study group. Primary prophylaxis in children with severe haemophilia A and B—Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts. Haemophilia. 2023;29(2):498-504. doi:10.1111/hae.14729

      Ljung R, de Kovel M, van den Berg HM on behalf of the PedNet study group. Primary prophylaxis in children with severe haemophilia A and B—Implementation over the last 20 years as illustrated in real-world data in the PedNet cohorts. Haemophilia. 2023;29(2):498-504. doi:10.1111/hae.14729

    • Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822. doi:10.1056/NEJMoa1803550

      Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822. doi:10.1056/NEJMoa1803550

    • HEMLIBRA Summary of Product Characteristics. Roche Registration Limited; 2022.

      HEMLIBRA Summary of Product Characteristics. Roche Registration Limited; 2022.

    • Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Supplementary materials. Blood Adv. 2022;6(24):6140-6150. doi:10.1182/bloodadvances.2022007458

      Kruse-Jarres R, Peyvandi F, Oldenburg J, et al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Supplementary materials. Blood Adv. 2022;6(24):6140-6150. doi:10.1182/bloodadvances.2022007458

    • HEMLIBRA Instructions For Use. Roche Registration Limited; 2022.

      HEMLIBRA Instructions For Use. Roche Registration Limited; 2022.

    • Doyle GR, McCutcheon JA. Clinical Procedures for Safer Patient Care. Victoria, BC: BCcampus. 2015. Retrieved from https://opentextbc.ca/clinicalskills/

      Doyle GR, McCutcheon JA. Clinical Procedures for Safer Patient Care. Victoria, BC: BCcampus. 2015. Retrieved from https://opentextbc.ca/clinicalskills/

    • Amano K, Fujii T, Sawada A, et al. TSUBASA Study: evaluating association of physical activity and bleeding events in people with haemophilia A without factor VIII inhibitors receiving emicizumab. Haemophilia. 2025;31(4):703-712. doi:10.1111/hae.70070

      Amano K, Fujii T, Sawada A, et al. TSUBASA Study: evaluating association of physical activity and bleeding events in people with haemophilia A without factor VIII inhibitors receiving emicizumab. Haemophilia. 2025;31(4):703-712. doi:10.1111/hae.70070

    • Kruse-Jarres R, Castaman G, Di Minno M, et al. Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: a second interim analysis of the BEYOND ABR study. Presented at the 67th American Society of Hematology (ASH) Annual Meeting; December 2025; Orlando, FL.

      Kruse-Jarres R, Castaman G, Di Minno M, et al. Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis: a second interim analysis of the BEYOND ABR study. Presented at the 67th American Society of Hematology (ASH) Annual Meeting; December 2025; Orlando, FL.

    • Shima M, Takedani H, Kitsukawa K, et al. AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis. Res Pract Thromb Haemost. 2025;9(8):103228. doi:10.1016/j.rpth.2025.103228

      Shima M, Takedani H, Kitsukawa K, et al. AOZORA study: 3-year interim analysis of safety and joint health in pediatric people with hemophilia A receiving emicizumab prophylaxis. Res Pract Thromb Haemost. 2025;9(8):103228. doi:10.1016/j.rpth.2025.103228

    • Mathias M, Kelly AM, Alamelu J, et al. PB0204 - Emicizumab prophylaxis in previously untreated and minimally treated boys with severe haemophilia A: summary of United Kingdom experience. Abstract presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; Bangkok, Thailaind; 2024.

      Mathias M, Kelly AM, Alamelu J, et al. PB0204 - Emicizumab prophylaxis in previously untreated and minimally treated boys with severe haemophilia A: summary of United Kingdom experience. Abstract presented at: International Society on Thrombosis and Haemostasis (ISTH) Congress; Bangkok, Thailaind; 2024.

    • de Kovel M, Kenet G, Motwani J, et al. Emicizumab prophylaxis in pups and mtps with severe haemophilia: the pednet real world experience in 80 infants. Blood. 2025;146(suppl 1):305. doi:10.1182/blood-2025-305

      de Kovel M, Kenet G, Motwani J, et al. Emicizumab prophylaxis in pups and mtps with severe haemophilia: the pednet real world experience in 80 infants. Blood. 2025;146(suppl 1):305. doi:10.1182/blood-2025-305

    • Poon M-C, Lee A, Germini F, et al. Experience with emicizumab among people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. Presented at: American Society of Hematology Annual Meeting; December 2023; San Diego, CA. doi:10.1182/blood-2023-174057

      Poon M-C, Lee A, Germini F, et al. Experience with emicizumab among people with hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. Presented at: American Society of Hematology Annual Meeting; December 2023; San Diego, CA. doi:10.1182/blood-2023-174057

    • Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials. Res Pract Thromb Haemost. 2024;8(3):102405. doi:10.1016/j.rpth.2024.102405

      Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials. Res Pract Thromb Haemost. 2024;8(3):102405. doi:10.1016/j.rpth.2024.102405

    • Buckner T, Daoud N, Lee L, et al. PB0625 Emicizumab prophylaxis in people with hemophilia A aged >50 years with comorbidities: experience from the ATHN 7 Hemophilia Natural History Study. Res Pract Thromb Haemost. 2023;7(suppl 2):636. doi:10.1016/j.rpth.2023.101210

      Buckner T, Daoud N, Lee L, et al. PB0625 Emicizumab prophylaxis in people with hemophilia A aged >50 years with comorbidities: experience from the ATHN 7 Hemophilia Natural History Study. Res Pract Thromb Haemost. 2023;7(suppl 2):636. doi:10.1016/j.rpth.2023.101210

    • Hermans C, Ventriglia G, Obaji S, et al. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis. Res Pract Thromb Haemost. 2023;7(8):102239. doi:10.1016/j.rpth.2023.102239

      Hermans C, Ventriglia G, Obaji S, et al. Emicizumab use in females with moderate or mild hemophilia A without factor VIII inhibitors who warrant prophylaxis. Res Pract Thromb Haemost. 2023;7(8):102239. doi:10.1016/j.rpth.2023.102239

    • Buckner TW, Carpenter SL, Daoud N, et al. Safety and effectiveness of emicizumab in people with haemophilia A enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026;32(1):63-70. doi:10.1111/hae.70151

      Buckner TW, Carpenter SL, Daoud N, et al. Safety and effectiveness of emicizumab in people with haemophilia A enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026;32(1):63-70. doi:10.1111/hae.70151

    • Castaman G, Croteau SE, Quon D, et al. A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors. Res Pract Thromb Haemost. 2025;9(1):102693. doi:10.1016/j.rpth.2025.102693

      Castaman G, Croteau SE, Quon D, et al. A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors. Res Pract Thromb Haemost. 2025;9(1):102693. doi:10.1016/j.rpth.2025.102693

    • Kiialainen A, Niggli M, Kempton C, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022;28(6):1033-1043. doi:10.1111/hae.14642

      Kiialainen A, Niggli M, Kempton C, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022;28(6):1033-1043. doi:10.1111/hae.14642

    • Manco-Johnson MJ, Le B, Acharya S, et al. Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort. Blood Vessel Thromb Hemost. 2025;2(3):100047. doi:10.1016/j.bvth.2025.100047

      Manco-Johnson MJ, Le B, Acharya S, et al. Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort. Blood Vessel Thromb Hemost. 2025;2(3):100047. doi:10.1016/j.bvth.2025.100047

    • Nogami K, Fujii T, Sawada A, et al. TSUBASA study: A prospective study evaluating the association between physical activity and bleeding events, quality of daily life, and safety in people with hemophilia A without FVIII inhibitors. Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting; December 7–10, 2024; San Diego, CA.

      Nogami K, Fujii T, Sawada A, et al. TSUBASA study: A prospective study evaluating the association between physical activity and bleeding events, quality of daily life, and safety in people with hemophilia A without FVIII inhibitors. Poster presented at: 66th American Society of Hematology (ASH) Annual Meeting; December 7–10, 2024; San Diego, CA.

    • Nogami K, Fujii T, Sawada A, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int J Hematol. 2024;119(1):14-23. doi:10.1007/s12185-023-03679-8

      Nogami K, Fujii T, Sawada A, et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. Int J Hematol. 2024;119(1):14-23. doi:10.1007/s12185-023-03679-8

    • St-Louis J, Abad A, Funk S, et al. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: a multicenter international study. Res Pract Thromb Haemost. 2022;6(2):e12690. doi:10.1002/rth2.12690

      St-Louis J, Abad A, Funk S, et al. The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: a multicenter international study. Res Pract Thromb Haemost. 2022;6(2):e12690. doi:10.1002/rth2.12690

    Top
    +